CARE Ratings Limited
Quality (92/100) does the heavy lifting; valuation (15/100) is the drag.
ExpensiveOvervaluedStocksWizard rates CARE Ratings Limited a Hold, scoring 45/100 on our blended model. We put fair value near ₹1,098.91; at ₹1,709.5 that leaves roughly 36% downside, so the stock screens overvalued by 36%. On 29.6x trailing earnings it sits pricier than the Financial Services median of about 24.3x. The price is about 4% below its 52-week high of ₹1,785.38 and 22% above the low of ₹1,400.72. Financial health scores 96/100, with a Piotroski F-score of 4/9. The average analyst target of ₹2,130 implies about 25% upside across 1 analysts. It clears 9 of 12 investability checks, with durability 92, valuation 29 and momentum 75 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹879.13.
Analyst views
1-year price
EOD · 2026-07-3152-week range
-4.25% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Hold45Piotroski F-score 4/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Pass: ROE above 15%: 19.8%
- Pass: Low debt (D/E < 0.5): 0.03x
- Pass: Positive free cash flow
- Pass: Revenue growth > 10%: 19%
- Pass: Earnings growing: 24%
- Pass: Net margin ≥ 10%: 36.2%
- Pass: Current ratio > 1.5: 5.75
- Fail: Below our fair value
- Fail: Margin of safety ≥ 20%
- Pass: Above 200-day average
- Pass: Above 50-day average
- No data: Positive 1-year return
- No data: Altman Z in safe zone
- Fail: Piotroski ≥ 7: 4/9
Quarterly results
Annual financials
Shareholding
- Promoter17.0%
- Institutions35.4%
- Public & other47.6%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Strong return on equity (19.8%).
- Lightly leveraged balance sheet.
- Healthy profit margin (36.2%).
Opportunities
- Earnings growing (24% YoY).
- Revenue growing (19% YoY).
Bear case
Threats
- Rich valuation versus sector peers.
- Trades ~36% above our estimated fair value.
About CARE Ratings Limited
CARE Ratings Limited is a credit rating agency operating in India and internationally. It rates bank loans, debt instruments, bonds, commercial papers, corporate bonds, debentures, InvITs, non-convertible debentures, certificates of deposit, mutual funds, hybrid instruments, and structured credit products.
CARE Ratings Limited — frequently asked questions
Is CARE Ratings Limited a buy, hold or sell?
StocksWizard currently rates CARE Ratings Limited (CARERATING) a Hold, based on a blended score of 45/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is CARE Ratings Limited's fair value?
Our blended DCF and relative-valuation model estimates CARE Ratings Limited's fair value at about ₹1,098.91, versus a current price of ₹1,709.5 — roughly 36% downside. On that basis the stock looks overvalued by 36%.
Is CARE Ratings Limited financially healthy?
CARE Ratings Limited scores 96/100 on our financial-health model, with a Piotroski F-score of 4/9.
How has CARE Ratings Limited's share price performed?
CARE Ratings Limited is up 3% over three months, and last traded at ₹1,709.5. Past performance doesn't predict future returns.
More in Financial Services
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.